Hanmi Pharmaceutical Earnings Strength Signals Obesity Growth Hanmi Pharmaceutical is rated Buy as strong revenue and 59.6% gross margin offset a 36% YoY operating profit drop; investors bet execution and partnerships will stabilize operating earnings. 2026년 09월 08일 English
